Genomics is facilitating a deeper understanding of cancer biology and through clinical research, new biomarkers are emerging that pave the way for next-generation therapeutics to help fight cancer in a more personalized way.
In this webinar, Sandip Patel, MD will provide a review of biomarker research and discoveries in the field of Immunotherapy and Garret Hampton, PhD will discuss Illumina’s vision for Oncology and share how genomics will enable broader availability of comprehensive tumor sequencing to explore complex biomarkers and assess tumor mutational burden.
Explore our smallest and most cost-effective sequencer ever. Join Bellal Moghis and Gary Schroth as they introduce our newest system—iSeq 100. They’ll walk through installation and also review applications and methods. Find out how you can make the most of your new lab partner.
With the dramatically increasing amount of sequence data generation and the significant reduction of sequencing costs, rapid, easy, and accurate data analytics becomes the critical bottleneck in adopting next-generation sequencing (NGS) in the public health sector. To this end, CosmosID has developed a cloud-based microbial genomics platform featuring with world’s largest curated genome databases and scaling computational power to keep pace with the ever-increasing amount of data generation. The platform brings together the most comprehensive and ultrafast “sequence to answer” workflow for easy, accurate, and highly resolved profiling of cross-disciplinary microbiome data. In this webinar, various aspects of the platform will be presented with reference to recent studies on water and wastewater treatment, food safety, molecular epidemiology, and multi-kingdom microbiome profiling and characterization. Key technologies that will be showcased include strain-level metagenomics, metatranscriptomics, metagenomic assembly, and molecular sub-typing.
See what happens when a leading library prep is optimized to run on next-generation sequencing (NGS) systems from Illumina. Join Mitu Chaudhary and Claire White as they present data to demonstrate the robust performance of AmpliSeq for Illumina from a wide variety of sample types.
The latest sequencing technologies enable unprecedented throughput and redefine limits for many labs. To adapt, these labs must redefine how they work – by automating tasks to reduce touchpoints and by simplifying workflows with integration and robust analysis tools. In this webinar, we describe BaseSpace™ Sequence Hub and how the newest features support high throughput, high-volume sequencing. We demonstrate how customers can progress from flowcell loading to variant analysis with zero touchpoints by using the Whole Genome Sequencing or Edico Genome DRAGEN apps. Additionally, we describe how the integration with BaseSpace™ Variant Interpreter enables users to interpret and generate reports of identified variants.
Pharmacogenetic (PGx) testing enables researchers to understand a
person’s genetic propensity for a therapeutic response or an adverse
reaction to particular medications. Recently the NIH’s Precision
Medicine Initiative has begun a nationwide effort to individualize a
subject’s treatment program, while the FDA has already included PGx
information in over one hundred drug labels. Serious drug reaction
events are likely to become more prevalent as more drugs become
available and the number of pharmaceuticals each person is taking
increases. To understand the occurrence of these events, sequencing
genomic regions associated with metabolism of a wide-spectrum of drug
classes can help inform clinical researchers, and better characterize
the frequency of known and novel haplotypes within validated genes
involved in drug metabolism pathways.
In this presentation, we will describe a method and workflow for targeted pharmacogenetic gene sequencing using Kailos’ TargetRichTM PGxComplete assay.
The Webinar Series will feature HLA laboratory directors presenting
case studies from samples prepared with TruSight™ HLA, sequenced with
Illumina next-generation sequencing (NGS) MiSeq or MiniSeq systems,
and analyzed using TruSight HLA Assign software. Presentations will be
followed by an interactive question and answer session.
The webinar will offer participants:
The latest NovaSeq advancements have arrived—delivering unprecedented scalability and flexibility for next-generation sequencing (NGS). Discover how the S4 flow cell allows you to use the NovaSeq 6000 System to take your research to the next level.
Join Gary Schroth, Illumina Distinguished Scientist, to learn about these latest advancements with the NovaSeq 6000 System. See how the S4 can provide you the highest throughput of any sequencer. Finally, with the new NovaSeq Xp workflow, you can expand your research, giving you more flexibility than ever before.
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight™ HLA, sequenced with Illumina next-generation sequencing (NGS) MiSeq or MiniSeq systems, and analyzed using TruSight HLA Assign software. Presentations will be followed by an interactive question and answer session.
The webinar will offer participants:
Dr Dolly Tyan will present on the Stanford Immunogenetics labs’ experience validating TruSight® HLA v2 for NGS HLA typing and validation of automation for TruSight HLA library prep. Dr Tyan will also share a case study to illustrate the utility of NGS HLA typing test results in solid organ transplantation research.
This presentation is part of the TruSight HLA Webinars Series which features HLA lab directors presenting case studies from samples prepared with TruSight HLA, sequenced with Illumina next-generation sequencing (NGS) MiSeq® or MiniSeq® systems, and analyzed using TruSight HLA Assign™ software.
Medical societies now recommend that all women, regardless of age, be offered screening and diagnostic testing for aneuploidy during pregnancy.1-2 Noninvasive prenatal testing (NIPT) is a newer screening option that utilizes the presence of cell-free DNA in a pregnant woman’s blood originating from the pregnancy. Whole-genome sequencing-based NIPT can screen for common aneuploidies (trisomy 21, trisomy 18, trisomy 13, and certain sex chromosome aneuploidies) with greater accuracy than other available screening modalities, resulting in a significant reduction in false positive rates and, subsequently, potential reduction in invasive procedures in healthy pregnancies.3
In this webinar, Tina Ziainia, MD, FACOG, an Obstetrician-Gynecologist affiliated with Sharp HealthCare, provides insight and expertise on successfully implementing NIPT into a busy practice. Having been in practice for over 17 years and having offered NIPT since 2013, she’ll also discuss prenatal screening options, review the latest ACOG and ACMG screening guidelines, and identify helpful resources for both you and your patients.
1. Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstet Gynecol. 2016;127(5):979-981.
2. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal
screening for fetal aneuploidy, 2016 update: a position statement of
the American College of Medical Genetics and Genomics. Genet
Med. 2016: doi:10.1038/gim.2016.97.
3. Bianchi DW, Rava RP, Sehnert AJ. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;371(6):578.
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight HLA, sequenced with Illumina next-generation sequencing (NGS) MiSeq or MiniSeqvsystems, and analyzed using TruSight HLA Assign software. Presentations will be followed by an interactive question and answer session.
The webinar will offer participants:
Brugada Syndrome belongs to a family of rare inherited cardiac disorders that can lead to sudden cardiac death. Rare genetic variants in the SCN5A gene can be identified in ~20%* of cases with Brugada Syndrome, while the genetic basis in the others remains unresolved.
Ongoing studies, combining data from multiple genomic methods, are helping to elucidate the genetic basis of Brugada Syndrome and other complex cardiac disorders with the aim of improving patient care in the future.
Register for the webinar to hear Professor Connie Bezzina present data from her laboratory and ongoing collaborative studies with the Brugada Syndrome Genetics Consortium.
This webinar will provide an overview of the development, validation and clinical evaluation of PathoQuest’s iDTECT Blood. This CE IVD test represents an application of NGS-based shotgun metagenomics to the field of infectious disease diagnosis. The test provides microbiologists and clinicians a precision diagnostics tool allowing individualized antimicrobial treatment decisions in patients where current microbiological methods frequently fail to identify a responsible pathogen. Both the sample preparation and the bioinformatic pipeline have been optimized to provide high sensitivity and accuracy and an actionable report. Clinical results from a prospective study recently published in Clinical Microbiology and Infection will also be discussed.
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight HLA, sequenced with Illumina next-generation sequencing (NGS) MiSeq or MiniSeq systems, and analyzed using TruSight HLA Assign software. Presentations will be followed by an interactive question and answer session.
The webinar will offer participants:
Mechanisms of microbial pathogenicity have been extensively analyzed using a broad spectrum of methods, which are driven largely by the technologies available at that time. As animal experimentation gave way to in vitro methods, specific pathogens were systematically investigated as individual dominant clones and colonizers. With the arrival of next-generation sequencing, microbiomes of very diverse habitats are being described. Thus, the microbiome of newborns versus those of the elderly are now prescribed, also the transition and shift in complexity and specificity of bacteria from the oral cavity through to the gut compared to the skin and respiratory are now cataloged and mapped across communities and in response to stress and stimuli. This tremendous leap in deciphering the human microbiome has ushered a new era of microbiology in which formidable challenges in establishing the foundation of taxonomy, dynamics and function of the residential microbial communities dominate.
This talk will present the progress made in metagenomics and the use of largely unassembled sequences in constructing the microbial communities forming the human microbiome. The knowledge assembled from microbial whole genome sequences, and the metabolic traits of the human flora are perhaps the most significant framework for the construction of reference microbiomes that can drive research into how transient pathogens establish in new niches and drive the shift from health to disease.
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight HLA , sequenced with Illumina next-generation sequencing (NGS) MiSeq or MiniSeq systems, and analyzed using TruSight HLA Assign software.
Discover a new era of sequencing with the NovaSeq Series. Join us for a live webinar event to see firsthand how we are redefining what is possible with high-throughput sequencing. Built from the ground up to fulfill your scientific visions, the NovaSeq Series gives you the flexibility and scalability to complete projects faster and more economically than ever before across a broad range of applications.
Webinar at a glance
Illumina BaseSpace Correlation Engine and the Elsevier Pathway Studio are two separate big data mining solutions for two different and highly complementary data problems: unlocking the molecular findings in the ever-growing genomic data repositories and staying up to date on the latest domain-specific scientific literature at the same time. Correlation Engine lets you query a repository of more than 128,000 experimental gene signatures as well as computed disease, compound, and genetic perturbation signatures. Pathway Studio gives you access to one of the world’s largest automatically curated literature databases, updated weekly, and generated using its proprietary NLP MedScan technology.
Next-generation sequencing (NGS) is providing new tools to that are aimed at developing products to comprehensively profile cancer samples. However, as with any truly novel technology, payers likely will question the clinical utility of NGS and scrutinize testing coverage. Join us to hear Charles Mathews, Vice President of Boston Healthcare, review how reimbursement is likely to play out in the future for key applications of NGS technology in the oncology space.
As researchers seek to understand how the transcriptome shapes
biology, RNA-Seq is
becoming recognized as one of the most significant and powerful tools in modern science. With RNA-Seq, researchers can detect the fine architecture of the transcriptome, such as transcript isoforms, gene fusions, single nucleotide variants, and other features—without prior knowledge. In addition to RNA-Seq, methylation sequencing can provide insights into the regulation of RNA and the temporal and spatial expression of gene products. By combining both RNA and methylation sequencing, researchers who study complex disease, cancer, and other biological systems will have a more complete picture of the transcriptome and its underlying regulatory features.
In this live webinar, we discuss the RNA-Seq and Methyl-Seq workflows that can help researchers drive breakthroughs and understanding in the area of gene expression and gene regulation. Join our gene expression and methylation experts as they review how researchers are driving discovery and learn how our workflows can help your lab leverage the power of next-generation sequencing.
It is important for health care professionals who offer noninvasive prenatal testing (NIPT) to understand the advantages and disadvantages of various assays currently used for NIPT. During this webinar, Dr Yuval Yaron will provide insight on the unique features of a whole-genome sequencing (WGS) approach for NIPT. He will review recent clinical experience data, discuss the impact of NIPT test failures, and review quality metrics that are utilized to analyze and report NIPT results.
Join Dr. Jamuar as he discusses the optimal technique for the detection of somatic mosaicism. He’ll evaluate the limitations of Sanger sequencing and highlight the advantages of targeted next-generation sequencing (NGS), sharing findings from his paper, Somatic Mutations in Cerebral Cortical Malformations, which was published in the New England Journal of Medicine.
Webinar at a glance:
Dr. Petrosino is exploring the comprehensive taxonomic and functional changes in the microbiome between birth and Type-1 Diabetes onset in over 22,000 samples from 820 cases and controls (1:1 match) in the TEDDY (The Environmental Determinants of Diabetes in the Young) international prospective cohort.
Advanced analyses of 16S rRNA gene, and bacterial/viral metagenomic data will be presented in this webinar.
Today’s complex genomic research questions demand a depth of
information beyond the capabilities of traditional DNA sequencing
technologies. Next-generation sequencing (NGS) has rapidly been
adopted as an important research tool, enabling previously unanswered
questions to be addressed.
Illumina next-generation sequencing utilizes a fundamentally
different approach from the classic Sanger chain-termination method.
It leverages sequencing by synthesis (SBS) technology – tracking the
addition of labelled nucleotides as the DNA chain is copied – in a
massively parallel fashion.
Watch our on demand webinar to find out more on how NGS can help you gain greater insight from your studies, save time, and be more confident in your results.
Recent studies on colorectal cancer (CRC) have elucidated four CRC consensus molecular subtypes with potential to predict outcome and stratify patients for therapy. Oncogenomics research by Enzo Medico, MD, PhD, from Candiolo Cancer Institute in Torino, describes how his laboratory is using integrative genomic techniques in cancer research to transform the future of CRC therapy.
Next Generation Sequencing (NGS) methods are arguably responsible for the establishment of the field of metagenomics. Significantly lower nucleic acid input requirements have made it possible to sample microbial communities that would have been deemed undetectable just a few years ago. In addition to technological advancements, the continued decline in the cost of sequencing has made it feasible to survey the thousands of samples necessary for metagenomic analyses. To meet the throughput demands of these studies, we have automated NGS sample processing methods from nucleic acid extraction, through library normalization, and pooling.
Here, we will present automated methods for 16S rDNA amplicon and whole genome shotgun sequencing as well as discuss the impact of automation on quality. The resulting sequencing reads from both approaches were compared for quality metrics using our standard quality matrix (Q30, Cluster Density, number of mapped reads, etc.)
Subsequently, sequencing reads were used for taxonomic identification and a comparative analysis. Although both automated methods offer a significant benefit in throughput, we found the reduction in the risk of human error far outweighs all other benefits. Furthermore, utilization of automated liquid handling reduces the risk of contamination.
Learn how the UCSF Center for Advanced Technology transitioned from the HiSeq 2500 System to the HiSeq 4000 System. Eric Chow, PhD will highlight some of the current projects that they are running on the HiSeq 4000 System, such as the metagenomic analysis of complex samples, ATAC-seq, and CRISPR screens. Discover how the HiSeq 4000 System delivers cost-effective sequencing for a multitude of library types.
Simplifying and Expediting Genomic Workflows with Integrated Informatics.
Until now, managing, analyzing, and interpreting genomic data has been an arduous process that required disparate data systems and the need to assemble a diverse set of software applications.
In this succinct webinar, we address how BaseSpace Variant Interpreter, the newest member of the BaseSpace Informatics Suite, can help clinical research labs quickly identify, annotate, and classify disease-relevant variants and summarize significant findings in one report. Integrated with BaseSpace Sequence Hub, BaseSpace Variant Interpreter enables rapid extraction to biological insight while increasing a genomic clinical research lab’s operational efficiency with a scalable secure solution.
This webinar is part of a series exploring BaseSpace Informatics Suite. Details of additional events will be presented during the webinar.
Join us as we walk through two of the applications of BaseSpace Informatics Suite, the integrated informatics solution to enable genomic research and the future of precision medicine. Andrew and Jill will show you how to simplify and expedite genomic workflows with integrated informatics using both BaseSpace Clarity LIMS and BaseSpace Sequence Hub.
Webinar at a glance:
Integration of the two applications
|The HiSeq 3000 and 4000 Sytems have set a new
standard in high-throughput genomics by extending the power of
patterned flow cell technology for a broad range of
applications. In a live demonstration, Dr. Godinez will provide
a comprehensive overview of the exome sequencing
Monogenic diseases are frequent causes of neonatal morbidity and mortality. Over 3,500 monogenic diseases have been characterized, many of which feature clinical and genetic heterogeneity. Since disease presentation at birth is often undifferentiated, there is an immense need for molecular diagnosis in infants. Disease progression in newborns is often fast and heterogeneous, so molecular diagnosis must occur rapidly for relevant clinical decision making. Here, we describe 50-hour differential diagnosis of genetic disorders by whole genome sequencing (WGS), featuring substantially automated bioinformatic analysis. This is intended to be a prototype for deployment in neonatal intensive care units.